Next-Gen CAR-T Cell Therapy Shows Promise for Refractory B-Cell ALL
- * Rapcabtagene Autoleucel (YTB323) in r/r B-ALL: A Phase 1 evaluation of safety and efficacy.
- * Provided by: Vall d'Hebron Institute of Oncology (https://medicalxpress.com/partners/vall-d-hebron-institute-of-oncology/) * Website: https://vhio.net/
- * Next-gen CAR-T cell therapy shows early promise in patients with refractory B-cell acute lymphoblastic leukemia.
Here’s a breakdown of the details provided in the text:
Research Presentations:
* Rapcabtagene Autoleucel (YTB323) in r/r B-ALL: A Phase 1 evaluation of safety and efficacy. (presentation ID: 811 – https://meetings-api.hematology.org/api/abstract/vmpreview/299877)
* CAR T cells vs. Bispecific Antibodies (Infectious Complications): A comparison of infectious complications in patients wiht relapsed/refractory large B-cell lymphoma. (Presentation ID: 782 – https://meetings-api.hematology.org/api/abstract/vmpreview/298842)
Source:
* Provided by: Vall d’Hebron Institute of Oncology (https://medicalxpress.com/partners/vall-d-hebron-institute-of-oncology/)
* Website: https://vhio.net/
Citation (for printing):
* Next-gen CAR-T cell therapy shows early promise in patients with refractory B-cell acute lymphoblastic leukemia.
In essence, this text is about new research on CAR-T cell therapy, specifically focusing on its use in treating B-cell acute lymphoblastic leukemia and large B-cell lymphoma. The information is sourced from presentations at a hematology meeting and provided by the Vall d’Hebron Institute of Oncology.